Meier P, Burnier M
Service de néphrologie et Consultation d'hypertension, CHUV, 1011 Lausanne.
Rev Med Suisse. 2006 Sep 13;2(78):2047-50, 2052-3.
Lercanidipine is a new highly lipophylic dihydropyrdine derivative of the third generation with equal efficacy but an improved tolerability profile. Comparative therapeutic trials have shown that it is as effective as other dihydropyridines, in particular amlodipine, beta-blockers, and angiotensin-converting enzyme inhibitors. Lercanidipine is well tolerated, with most treatment-emergent events related to vasodilation. Lercanidipine produces less reflex tachycardia and peripheral oedema. Common adverse events included headache and flushing. Because of its efficacy and favorable safety profile, lercanidipine has the potential to improve blood pressure control in a wide range of patients, including those who have not responded to, or who have been unable to tolerate other antihypertensive agents.
乐卡地平是一种新型的第三代高度亲脂性二氢吡啶衍生物，疗效相当，但耐受性有所改善。对比治疗试验表明，它与其他二氢吡啶类药物，特别是氨氯地平、β受体阻滞剂和血管紧张素转换酶抑制剂一样有效。乐卡地平耐受性良好，大多数治疗中出现的事件与血管舒张有关。乐卡地平引起的反射性心动过速和外周水肿较少。常见的不良事件包括头痛和面部潮红。由于其疗效和良好的安全性，乐卡地平有可能改善广泛患者的血压控制，包括那些对其他抗高血压药物无反应或无法耐受的患者。
